Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers

Journal of the National Cancer Institute

Volumn 103, Issue 7, 2011, Pages 562-570

  Farhat, Ghada N ^a   Cummings, Steven R ^a   Chlebowski, Rowan T ^b   Parimi, Neeta ^a   Cauley, Jane A ^c   Rohan, Thomas E ^d   Huang, Alison J ^e   Vitolins, Mara ^f   Hubbell, F Allan ^g   Manson, Joann E ^h   Cochrane, Barbara B ⁱ   Lane, Dorothy S ^j   Lee, Jennifer S ^k  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j STONY BROOK UNIVERSITY   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; SEX HORMONE; TESTOSTERONE;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER RISK; COHORT ANALYSIS; ESTRADIOL BLOOD LEVEL; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; LIFESTYLE; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; PRIORITY JOURNAL; RACE DIFFERENCE; RADIOIMMUNOASSAY; TESTOSTERONE BLOOD LEVEL;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHEMILUMINESCENT MEASUREMENTS; CONFOUNDING FACTORS (EPIDEMIOLOGY); ESTRADIOL; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 79953893331     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr031     Document Type: Article

References (33)

1. Setiawan VW, Monroe KR, Wilkens LR, et al. Breast cancer risk factors defned by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol. 2009;169(10):1251-1259.
2. Chlebowski RT, Anderson GL, Lane DS, et al. Predicting risk of breast cancer in postmenopausal women by hormone receptor status. J Natl Cancer Inst. 2007;99(22):1695-1705. (Pubitemid 351767220)
3. Cummings SR, Lee JS, Lui LY, et al. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomarkers Prev. 2005;14(5): 1047-1051. (Pubitemid 40656446)
4. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE. Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst. 2004;96(3):218-228. (Pubitemid 38263181)
5. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606-616. (Pubitemid 34498648)
6. Cummings SR, Tice JA, Bauer S, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst. 2009;101(6):384-398.
7. Sieri S, Krogh V, Bolelli G, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev. 2009;18(1):169-176.
8. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst. 2004;96(24): 1856-1865. (Pubitemid 40081323)
9. Kaaks R, Rinaldi S, Key TJ, et al. Postmenopausal serum androgens, oes-trogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 2005;12(4):1071-1082. (Pubitemid 41815798)
10. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer. 2004;90(1):153-159. (Pubitemid 38174955)
11. Brettes JP, Mathelin C. [Dual effects of androgens on mammary gland]. Bull Cancer. 2008;95(5):495-502. (Pubitemid 351891913)
12. Dimitrakakis C, Bondy C. Androgens and the breast. Breast Cancer Res. 2009;11(5):212.
13. Zeleniuch-Jacquotte A, Toniolo P, Levitz M, et al. Endogenous estrogens and risk of breast cancer by estrogen receptor status: a prospective study in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 1995;4(8): 857-860.
14. The Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials. 1998;19(1):61-109.
15. The SEER Program Code Manual. NIH Publication No. 92-1999. Cancer Statistics Branch, Surveillance Program, Division of Cancer Prevention and Control, National Cancer Institute, US Department of Health and Human Services, Public Health Service, National Institutes of Health; Washington, DC; 1992.SEER Program: Comparative Staging Guide for Cancer, version 1.1. NIH Publication No. 93-3640. US Department of Health and Human Services, Public Health Service, National Institutes of Health; Washington, DC; 1993.
16. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003;13(9) (suppl):S5-S17. (Pubitemid 37324175)
17. Probst-Hensch NM, Ingles SA, Diep AT, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer. 1999;6(2):165-173. (Pubitemid 29260048)
18. Sodergard R, Backstrom T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982;16(6): 801-810. (Pubitemid 13228095)
19. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-3672. (Pubitemid 30645223)
20. Rinaldi S, Geay A, Dechaud H, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev. 2002;11(10, pt 1): 1065-1071. (Pubitemid 35192658)
21. Manson JE, Greenland P, LaCroix AZ, et al. Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med. 2002;347(10):716-725. (Pubitemid 35203902)
22. Gail MH, Brinton LA, Byar DP, et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst. 1989;81(24):1879-1886. (Pubitemid 20026073)
23. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90(18):1371-1388. (Pubitemid 28439961)
24. Prentice RL. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika. 1986;73(1):1-11.
25. Beattie MS, Costantino JP, Cummings SR, et al. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). J Natl Cancer Inst. 2006;98(2):110-115. (Pubitemid 43159965)
26. Ortmann J, Prifti S, Bohlmann MK, et al. Testosterone and 5 alpha-dihydrotestosterone inhibit in vitro growth of human breast cancer cell lines. Gynecol Endocrinol. 2002;16(2):113-120. (Pubitemid 34496877)
27. Dimitrakakis C, Zhou J, Wang J, et al. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. 2003;10(4): 292-298. (Pubitemid 36870501)
28. Zhou J, Ng S, Adesanya-Famuiya O, Anderson K, Bondy CA. Testosterone inhibits estrogen-induced mammary epithelial proliferation and suppresses estrogen receptor expression. FASEB J. 2000;14(12):1725-1730.
29. Jayo MJ, Register TC, Hughes CL, et al. Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. J Soc Gynecol Investig. 2000;7(4):257-265. (Pubitemid 30665624)
30. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in post-menopausal women. Arch Intern Med. 2006;166(14):1483-1489. (Pubitemid 44125867)
31. Ness RB, Albano JD, McTiernan A, Cauley JA. Infuence of estrogen plus testosterone supplementation on breast cancer. Arch Intern Med. 2009; 169(1):41-46.
32. Davis SR, Moreau M, Kroll R, et al. Testosterone for low libido in post-menopausal women not taking estrogen. N Engl J Med. 2008;359(19): 2005-2017.
33. Dimitrakakis C, Jones RA, Liu A, Bondy CA. Breast cancer incidence in postmenopausal women using testosterone in addition to usual hormone therapy. Menopause. 2004;11(5):531-535. (Pubitemid 40362151)